A Phase 3 interventional study of Aclidinium Bromide / Formoterol Fumarate and Salmeterol / Fluticasone in Chronic Obstructive Pulmonary Disease (COPD), sponsored by AstraZeneca. Completed at 126 sites in 14 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2016-03-07.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing aclidinium bromide in Pulmonary Disease, Chronic Obstructive — none open to participants now, none under way, none of them phase 3. aclidinium bromide · Pulmonary Disease, Chronic Obstructive.
Among the 28 studies testing aclidinium bromide in Pulmonary Disease, Chronic Obstructive, this one is the 6th largest by enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2013, is one of 19 in phase 3, and was the 20th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →None of the 28 studies testing aclidinium bromide in Pulmonary Disease, Chronic Obstructive is open now. The open studies under Pulmonary Disease, Chronic Obstructive, anywhere →
aclidinium bromide: first FDA approval 2012 (TUDORZA PRESSAIR), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 933 is above the median of 62 across 3,840 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 561 across the 27 interventional studies. Of the 27 that completed or were terminated, 23 (85%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 28 have an industry lead sponsor. The 4 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca: 14 open now, 15 under way, 4 of them phase 3. Of 264 finished, 127 (48%) have results posted.
Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 37th largest by enrollment of the 194 interventional ones that give a count, is one of 14 that started in 2013, is one of 76 in phase 3, and was the 135th registered.
AstraZeneca’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 28 studies testing aclidinium bromide in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 284 in Pulmonary Disease, Chronic Obstructive:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to compare the efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate and salmeterol/fluticasone propionate in patients with chronic obstructive pulmonary disease (COPD)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Aclidinium Bromide 400 μg / Formoterol Fumarate 12 μg BID for 24 Weeks
Drug: Aclidinium Bromide / Formoterol Fumarate
Salmeterol 50 μg / Fluticasone propionate 500 μg BID for 24 Weeks
Drug: Salmeterol / Fluticasone
Drug pages: Aclidinium bromide · Formoterol
Drug pages: Salmeterol Xinafoate · Fluticasone
Also known as: Seretide, Advair
Peak Forced Expiratory Volume in One Second (FEV1) at Week 24
Peak FEV1 define at the highest value observed in the 3h after the morning IMP administration
Time frame: At Week 24
Transition Dyspnoea Index (TDI) Focal Score at Week 24
The TDI includes the same 3 categories as BDI and 7 ratings indicating the magnitude of the change from baseline in each category: from -3 ("major deterioration") to zero ("no change") to +3 ("major improvement"). Category scores are added to compute the Focal Score (from -9 to 9)
Time frame: At Week 24
This study was conducted at 140 activated sites. A total of 121 sites randomised patients. The first patient was screened in Oct 2013 and the last patient visit was in Aug 2014.
| Milestone | Aclidinium Bromide / Formoterol Fumarate | Salmeterol / Fluticasone |
|---|---|---|
| Started | 468 | 465 |
| Completed | 402 | 386 |
| Not completed | 66 | 79 |
| Withdrew: Other or progressive disease | 5 | 12 |
| Withdrew: Lack of efficacy | 7 | 5 |
| Withdrew: Withdrawal by subject | 23 | 24 |
| Withdrew: Lost to follow-up | 1 | 6 |
| Withdrew: Protocol violation | 8 | 9 |
| Withdrew: Adverse event | 22 | 23 |
Peak FEV1 define at the highest value observed in the 3h after the morning IMP administration
| Liters | Aclidinium Bromide / Formoterol Fumarate | Salmeterol / Fluticasone |
|---|---|---|
| Peak Forced Expiratory Volume in One Second (FEV1) at Week 24 | 1.655 ± 0.011 | 1.562 ± 0.011 |
The TDI includes the same 3 categories as BDI and 7 ratings indicating the magnitude of the change from baseline in each category: from -3 ("major deterioration") to zero ("no change") to +3 ("major improvement"). Category scores are added to compute the Focal Score (from -9 to 9)
| TDI Focal Score | Aclidinium Bromide / Formoterol Fumarate | Salmeterol / Fluticasone |
|---|---|---|
| Transition Dyspnoea Index (TDI) Focal Score at Week 24 | 1.9 ± 0.17 | 1.9 ± 0.17 |
Collected over 24 Weeks treatment + 2 weeks follow-up (±3 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aclidinium Bromide / Formoterol Fumarate | — | 35/467 (7.5%) | 124/467 (26.6%) |
| Salmeterol / Fluticasone | — | 33/466 (7.1%) | 135/466 (29%) |
| Event | Aclidinium Bromide / Formoterol Fumarate | Salmeterol / Fluticasone |
|---|---|---|
| COPD (exacerbation)Respiratory, thoracic and mediastinal disorders | 13/467 | 8/466 |
| PneumoniaInfections and infestations | 2/467 | 4/466 |
| Forearm fractureInjury, poisoning and procedural complications | 0/467 | 2/466 |
| HypertensionVascular disorders | 0/467 | 2/466 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 2/467 | 0/466 |
| AnaemiaBlood and lymphatic system disorders | 0/467 | 1/466 |
| Coronary Artery DiseaseCardiac disorders | 0/467 | 1/466 |
| Cardiac FailureCardiac disorders | 0/467 | 1/466 |
| Artrial fibrillationCardiac disorders | 1/467 | 1/466 |
| CataractEye disorders | 0/467 | 1/466 |
| Event | Aclidinium Bromide / Formoterol Fumarate | Salmeterol / Fluticasone |
|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 70/467 | 75/466 |
| HeadacheNervous system disorders | 28/467 | 32/466 |
| NasopharyngitisInfections and infestations | 26/467 | 28/466 |
Patients with more than 1 treatment were analysed in the Safety population with the actual treatment assigned; for this reason, the Overall Number of Baseline Participants in the safety population is different than the randomised population.
| Age, Customized(years) | Aclidinium Bromide / Formoterol Fumarate | Salmeterol / Fluticasone | Total |
|---|---|---|---|
| Age (years), mean (SD) | 63.5 ± 8.1 | 63.3 ± 7.5 | 63.4 ± 7.8 |
| Sex: Female, Male(Participants) | Aclidinium Bromide / Formoterol Fumarate | Salmeterol / Fluticasone | Total |
|---|---|---|---|
| Female | 160 | 166 | 326 |
| Male | 307 | 300 | 607 |
| Region of Enrollment(participants) | Aclidinium Bromide / Formoterol Fumarate | Salmeterol / Fluticasone | Total |
|---|---|---|---|
| Austria | 23 | 24 | 47 |
| Bulgaria | 30 | 32 | 62 |
| Canada | 12 | 6 | 18 |
| Czech Republic | 11 | 14 | 25 |
| France | 10 | 4 | 14 |
| Germany | 118 | 136 | 254 |
| Hungary | 50 | 48 | 98 |
| Italy | 6 | 5 | 11 |
| Lithuania | 17 | 10 | 27 |
| Netherlands | 11 | 11 | 22 |
| Poland | 67 | 55 | 122 |
| South Africa | 68 | 66 | 134 |
| Spain | 28 | 34 | 62 |
| United Kingdom | 16 | 21 | 37 |
Showing the first 100 of 126 sites across 14 countries. Choose a country and city above to see the rest.
The record gives a start of Sep 2013, a primary completion of Aug 2014 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2016, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Aclidinium bromide · Formoterol
Pulmonary Disease, Chronic Obstructive →